drugset / Trial / NCT01435772
Extension Study for Patients Who Have Participated in a BMN 701 Study
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This is a Phase 2 open-label, multiple dose study of BMN 701 administered by IV infusion every 2 weeks (qow) to patients with late-onset Pompe disease.
Timeline
- Start
- 2011-08-15
- Primary completion
- 2016-09-09
- Completion
- 2016-09-09
Outcome
Outcome not reported
Stopped: “The study was terminated because BioMarin decided to end the overall development program based on competing corporate priorities.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | REVEGLUCOSIDASE ALFA | Protein / enzyme biologic | 5 mg/kg | Intravenous |
| Subject | REVEGLUCOSIDASE ALFA | Protein / enzyme biologic | 10 mg/kg | Intravenous |
| Subject | REVEGLUCOSIDASE ALFA | Protein / enzyme biologic | 20 mg/kg | Intravenous |